Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Synthetic Biologics’ SYN-004 secures FDA breakthrough therapy status

pharmaceutical-technologyMay 16, 2017

Tag: CDI , Synthetic Biologics , FDA

PharmaSources Customer Service